Logo Logo

Publications by Kabashima, K.

Up a level
Export as [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date
Number of items: 3.

Journal article

Simpson, E. L.; Lacour, J.-P.; Spelman, L.; Galimberti, R.; Eichenfield, L. F.; Bissonnette, R.; King, B. A.; Thyssen, J. P.; Silverberg, J. I.; Bieber, T.; Kabashima, K.; Tsunemi, Y.; Costanzo, A.; Guttman-Yassky, E.; Beck, L. A.; Janes, J. M.; DeLozier, A. M.; Gamalo, M.; Brinker, D. R.; Cardillo, T.; Nunes, F. P.; Paller, A. S.; Wollenberg, A.; Reich, K. (2020): Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phaseIIItrials. In: British Journal of Dermatology, Vol. 183, No. 2: pp. 242-255

Silverberg, J. I.; Thyssen, J. P.; Paller, A. S.; Drucker, A. M.; Wollenberg, A.; Lee, K. H.; Kabashima, K.; Todd, G.; Schmid-Grendelmeier, P.; Bieber, T. (2017): What's in a name? Atopic dermatitis or atopic eczema, but not eczema alone. In: Allergy, Vol. 72, No. 12: pp. 2026-2030

Nemoto, O.; Furue, M.; Nakagawa, H.; Shiramoto, M.; Hanada, R.; Matsuki, S.; Imayama, S.; Kato, M.; Hasebe, I.; Taira, K.; Yamamoto, M.; Mihara, R.; Kabashima, K.; Ruzicka, T.; Hanifin, J.; Kumagai, Y. (2016): The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study. In: British Journal of Dermatology, Vol. 174, No. 2: pp. 296-304

This list was generated on Sun Feb 5 12:48:23 2023 CET.